SCHEMBL1199271

SCHEMBL1199271

O=C(O)c1ccc(Cc2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.57
SRD5A2 P31213 2/20 0.56
KDM4E B2RXH2 6/20 0.55
ALDH1A1 P00352 4/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
HDAC3 O15379 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC10 Q969S8 1/20 0.52
HDAC11 Q96DB2 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
HDAC9 Q9UKV0 1/20 0.52
HDAC5 Q9UQL6 1/20 0.52
RAB9A P51151 4/20 0.50
NPC1 O15118 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28708808 1.00 LTA4H (0.57) LTA4HSRD5A2KDM4EALDH1A1MEN1
SCHEMBL28715169 0.86 ALDH1A1 (0.56) LTA4HKDM4EALDH1A1MEN1KMT2A
SCHEMBL1198879 0.86 ALDH1A1 (0.56) LTA4HKDM4EALDH1A1MEN1KMT2A
SCHEMBL1198039 0.86 ALDH1A1 (0.72) LTA4HSRD5A2KDM4EALDH1A1MEN1
SCHEMBL1198172 0.86 KDM4E (0.54) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL31590332 0.86 KDM4E (0.54) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL1199358 0.85 KDM4E (0.53) LTA4HSRD5A2KDM4EALDH1A1MEN1
SCHEMBL1199693 0.84 RAB9A (0.65) LTA4HKDM4EALDH1A1MEN1KMT2A
SCHEMBL1198392 0.84 ALDH1A1 (0.52) LTA4HSRD5A2KDM4EALDH1A1MEN1
SCHEMBL1197869 0.84 RAB9A (0.69) KDM4EALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A LTA4H 3602/4885SRD5A2 69/4885KDM4E 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.